As pain management evolves, R.Ph.s can play a greater role
The pain management pharmaceuticals market in the U.S. is being driven by the continued development of selective cyclooxygenase-2 (COX-2) inhibitors, triptans, and extended-release formulations of opioid drugs, according to new analysis by the consulting firm of Frost & Sullivan. In 1997, the company released a similar report. In the intervening six years, the market has undergone dramatic changes.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
